Optovue Showcases World’s First OCT Angiography Metrics and Non-contact Method for Corneal Measurements at Vision Expo West

Company Introduces Non-mydriatic Ophthalmic Camera

LAS VEGAS–(BUSINESS WIRE)–#AngioAnalytics—Optovue,
the global leader in the development of optical coherence tomography (OCT)
and OCT angiography (OCTA),
will showcase AngioAnalytics™, the world’s first OCTA blood vessel
measurement technology to help clinicians manage diseases that cause
progressive blindness, and 3D PAR, its three-dimensional projection
artifact removal software at Vision Expo West 2018. The company will
also highlight its 9mm Epithelial Thickness Mapping (ETM), a wider
version of its non-contact, quantitative method for corneal epithelia
and stromal measurements, and debut its new non-mydriatic ophthalmic
camera, Vivicon, offering a touch-screen tablet interface with fully
automatic alignment and image capture.

Optovue recently received FDA 510(k) clearance for AngioAnalytics, and
expanded FDA clearance for ETM, which added the nine-millimeter ETM scan
to the previously available six-millimeter map, allowing for detection
of epithelial irregularities in an area that is about two-and-a-quarter
times that of the area covered by the six-millimeter scan.

“Optovue continues to advance the eye care industry with software such
as AngioAnalytics,” said Julie Rodman, O.D., M.S., FAAO, associate
professor at Nova Southeastern University College of Optometry. “This
technology allows for an objective assessment of the microvasculature,
which ultimately results in more timely detection of disease and
optimizes patient management.”

AngioAnalytics brings objective data and analysis to Optovue’s
commercially available AngioVue® OCTA technology that provides
high-resolution imaging of retinal blood vessels. Combined, the two
technologies create color-encoded maps of the vessel densities of the
retina or optic nerve, and provide analyses of areas where there is
blood vessel loss (non-perfusion), abnormal blood vessel growth (flow
area), and several parameters to assess change to the foveal avascular
zone, an area of the retina profoundly affected by diabetic retinopathy.
The AngioAnalytics software also provides trend analysis so that doctors
can objectively monitor retinal and vascular changes caused by disease
progression or from treatment.

Optovue’s ETM, now available on the Avanti® Widefield OCT system, is the
first and only FDA-cleared OCT product indicated to provide corneal
epithelial and stromal measurements that aid in the diagnosis,
documentation and management of ocular health and diseases in the adult
population. The measurement of corneal epithelial thickness is
recognized by eye care professionals as a vital part of assessing
patients for refractive surgery and following post-operative recovery,
as well as managing patients with progressive eye diseases and ocular
surface disorders.

“With epithelial thickness mapping, we are able to better diagnose,
monitor and treat our patients with keratoconus, dry eye, and
fluctuating vision following refractive or other anterior segment
surgeries,” said S. Barry Eiden, O.D., FAAO, FSLS, president and medical
director of North Suburban Vision Consultants, Ltd. “We have integrated
ETM into our patient consultation workflow and we are able to educate
and update our patients about their conditions very easily while also
adjusting any management protocols to optimize outcomes.”

Expanding its product offering for eye care providers, Optovue’s Vivicon
ophthalmic camera is an easy-to-use, non-mydriatic fundus camera that
includes fully automatic 3D tracking and image capture, making the
operation simple for technicians and comfortable for patients. Retinal
and external images can be reviewed on the touch-screen tablet or
exported to an exam lane or office network. The affordable Vivicon
camera is commercially available in the U.S.

“We are excited to introduce our new Vivicon ophthalmic camera at the
Vision Expo West, as it is a great venue conducive to meeting and
interacting with eye care professionals and showcasing new products,”
said Jay Wei, founder and chief executive officer of Optovue. “We are
also pleased to highlight AngioAnalytics technology as part of the
AngioVue System to aid physicians in the early detection and management
of sight-threatening eye diseases in the U.S. The information provided
by AngioAnalytics may help to change the clinical management of diabetic
retinopathy, age-related macular degeneration and other diseases that
progressively cause blindness for millions of people.

“With our ETM software, we are already witnessing a change in the way
physicians assess the cornea and we believe ETM will become an essential
part of anterior segment eye exams in daily clinical practice,”
continued Wei.

Optovue will debut the new Vivicon ophthalmic camera and also highlight
AngioAnalytics and ETM in booth # MS5035 at the Sands Expo & Convention
Center, Sept. 26-29, 2018.

About Optovue

Optovue,
Inc. is a privately held medical device company founded in 2003.
Headquartered in Fremont, Calif., the company is dedicated to the
advancement and commercialization of high-speed OCT and OCTA technology
used to facilitate the diagnosis and management of eye diseases, many of
which may lead to permanent blindness. Optovue is the first company to
develop and commercialize the pioneering OCTA
technology. To date, there are over 400 peer-reviewed publications
detailing the AngioVue® OCTA imaging technology and clinical
applications. The company has installed over 12,000 products worldwide.
For more information, visit www.optovue.com.

Contacts

For Optovue
Amy Cook, 925-200-2125
amy@amcpublicrelations.net